

Strides Board approves incremental investments in Stelis

23 September 2019 | News

Strides to acquire a controlling stake in Stelis with the infusion of new capital



Bengaluru based Strides Pharma Science Limited has announced that the Board of Directors of the Company have approved an additional investment up to a maximum of ~\$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma Private Limited (Stelis).

The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides' re-entry into sterile injectables business post the completion of the Company's non-compete period in December 2019.

As on date, Stelis has invested over ~\$160 million, of which ~\$ 91 million is represented by equity capital infused by Strides and its equity partners. Strides has invested ~\$ 35 million for a ~43% ownership in Stelis. With the aforementioned infusion up to ~\$ 40 million by Strides and pending equity commitments from the other partners, Stelis would have attained a critical size to break even at the operational level which is expected in the next 18 months.

Stelis was set up to pursue a global biopharmaceutical business with a strategy to develop competitively priced biopharma products and offer high-end CDMO services covering end-to-end biopharmaceutical value chain.

The principal shareholders of Stelis are Strides Pharma, Tenshi Life Sciences Private Limited (Integrated Life Sciences Company) and GMS Holdings (Group of diversified business and assets with a strong biopharma franchise in the MENA region).